Establishment Labs Holdings Inc. (ESTA) stock
ESTANasdaqOrthopedic, Prosthetic & Surgical Appliances & SuppliesFiscal year ends December 31
$69.51−0.31 (-0.44%)
Close on Nov 17, 2026Market cap $2.07BP/E –Yield –
Establishment Labs r&d expenses
Research and development expenses are spending on new products and technology.
Establishment Labs's R&D Expenses for the twelve months ending Sep 30, 2026 was $20.08M, up 0.6% year over year. For fiscal 2025 it was $20.25M, up 2.7% from the year before. The highest annual figure on record is $26.43M in fiscal 2023.
Annual r&d expenses
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $20.25M | +2.7% |
| FY2024 | Dec 31, 2024 | $19.71M | -25.4% |
| FY2023 | Dec 31, 2023 | $26.43M | +30.4% |
| FY2022 | Dec 31, 2022 | $20.27M | +10.7% |
| FY2021 | Dec 31, 2021 | $18.32M | +32.8% |
| FY2020 | Dec 31, 2020 | $13.79M | -8.0% |
| FY2019 | Dec 31, 2019 | $14.99M | +18.2% |
| FY2018 | Dec 31, 2018 | $12.69M | +84.8% |
| FY2017 | Dec 31, 2017 | $6.86M | – |
Quarterly r&d expenses
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | $4.31M | -5.3% |
| Q2 FY2026 | Jun 30, 2026 | $5.10M | -2.1% |
| Q1 FY2026 | Mar 31, 2026 | $5.24M | +3.7% |
| Q4 FY2025 | Dec 31, 2025 | $5.43M | +5.6% |
| Q3 FY2025 | Sep 30, 2025 | $4.56M | -5.1% |
| Q2 FY2025 | Jun 30, 2025 | $5.20M | -5.2% |
| Q1 FY2025 | Mar 31, 2025 | $5.06M | +18.3% |
| Q4 FY2024 | Dec 31, 2024 | $5.14M | -11.6% |
| Q3 FY2024 | Sep 30, 2024 | $4.80M | -32.6% |
| Q2 FY2024 | Jun 30, 2024 | $5.49M | -21.0% |
| Q1 FY2024 | Mar 31, 2024 | $4.27M | -34.6% |
| Q4 FY2023 | Dec 31, 2023 | $5.82M | -10.2% |
| Q3 FY2023 | Sep 30, 2023 | $7.13M | +34.8% |
| Q2 FY2023 | Jun 30, 2023 | $6.95M | +41.7% |
| Q1 FY2023 | Mar 31, 2023 | $6.53M | +81.6% |
| Q4 FY2022 | Dec 31, 2022 | $6.48M | +7.4% |
| Q3 FY2022 | Sep 30, 2022 | $5.29M | +36.2% |
| Q2 FY2022 | Jun 30, 2022 | $4.90M | +12.7% |
| Q1 FY2022 | Mar 31, 2022 | $3.60M | -11.1% |
| Q4 FY2021 | Dec 31, 2021 | $6.03M | +35.1% |
| Q3 FY2021 | Sep 30, 2021 | $3.88M | +42.3% |
| Q2 FY2021 | Jun 30, 2021 | $4.35M | +81.3% |
| Q1 FY2021 | Mar 31, 2021 | $4.05M | -3.6% |
| Q4 FY2020 | Dec 31, 2020 | $4.47M | +23.0% |
| Q3 FY2020 | Sep 30, 2020 | $2.73M | -27.7% |
| Q2 FY2020 | Jun 30, 2020 | $2.40M | -40.0% |
| Q1 FY2020 | Mar 31, 2020 | $4.20M | +17.2% |
| Q4 FY2019 | Dec 31, 2019 | $3.63M | -0.8% |
| Q3 FY2019 | Sep 30, 2019 | $3.78M | +19.0% |
| Q2 FY2019 | Jun 30, 2019 | $4.00M | +8.0% |
| Q1 FY2019 | Mar 31, 2019 | $3.58M | +66.9% |
| Q4 FY2018 | Dec 31, 2018 | $3.66M | +49.8% |
| Q3 FY2018 | Sep 30, 2018 | $3.17M | +121.0% |
| Q2 FY2018 | Jun 30, 2018 | $3.71M | +150.2% |
| Q1 FY2018 | Mar 31, 2018 | $2.15M | – |
| Q4 FY2017 | Dec 31, 2017 | $2.44M | – |
| Q3 FY2017 | Sep 30, 2017 | $1.44M | – |
| Q2 FY2017 | Jun 30, 2017 | $1.48M | – |
See a number that looks wrong?